AZN vs MEDP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.
Medpace exhibits strong operational health with a Piotroski F-Score of 7/9 and an exceptional ROE of 70.23%, reflecting a high-efficiency growth engine. However, the stock is significantly overvalued from a defensive standpoint, trading at $501.23 against a Graham Number of $74.63 and slightly above its growth-based intrinsic value of $451.35. While revenue and earnings growth remain robust, the high PEG ratio (2.98) and aggressive insider selling by the CEO and President suggest the current price may have peaked. The overall profile is that of a high-quality company trading at a premium valuation.
Compare Another Pair
Related Comparisons
AZN vs MEDP: Head-to-Head Comparison
This page compares AstraZeneca PLC (AZN) and Medpace Holdings, Inc. (MEDP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.